Recent economic developments in Europe have impacted the state of specialty pharmacy. Here is an overview of the fluid situation and a comparison with the United States specialty market.
Dimitris Dogramatzis, RPh, PhD
Advertisement
Articles by Dimitris Dogramatzis, RPh, PhD
The exploration of the freedom to operate in the specialty biopharmaceutical market, which requires specific steps and processes.
Advertisement
Latest Updated Articles
- The Importance of Freedom to Operate for Specialty Biopharmaceuticals
Published: February 22nd 2012 | Updated:
- Specialty Pharmacy in the European Union
Published: December 18th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
Ziftomenib Receives FDA Approval for Acute Myeloid Leukemia With NPM1 Mutations
3
The Dual Burden of CAR T-Cell Therapy: Financial and Time Toxicity in the Era of Precision Oncology
4
Giredestrant Plus Everolimus Extends Survival in ER+, HER2- Advanced Breast Cancer
5
